The overall risk of needing a total thyroidectomy was found to be 19.4% for patients undergoing lobectomy for indeterminate and high-risk thyroid nodule, according to a report published by Moore et al in the World Journal of Surgery. The study also found that 21% and 26.5% of patients originally referred for lobectomy had to be upgraded to total thyroidectomy during or immediately after surgery, respectively. These latest findings shed new light on the clinical reality of patients deemed suitable for unilateral thyroid lobectomy.
“The whole point of this research is realizing that more patients, based on their evaluation in the clinic, should be directed toward a total thyroidectomy to lessen the number of patients that need to return for a second operation,” said lead study author Allan Siperstein, MD, Chairman of the Department of Endocrine Surgery at Cleveland Clinic.
American Thyroid Association (ATA) guidelines are used in the preoperative evaluation of patients with thyroid cancer and suggest a risk-directed approach in determining the extent of surgery needed for thyroid cancer. According to ATA guidelines, total thyroidectomy and radioactive iodine treatment are recommended for high-risk tumors measuring more than 4 cm or lesions that exhibit adverse pathology. Lobectomy is usually considered suitable for smaller intrathyroidal tumors with no added risk factors.
“It has become recognized that we can be less aggressive with surgery and, if the nodule is appropriate, the guidelines recommend removing just half of the thyroid,” said Dr. Siperstein.
However, he also noted that a significant number of patients with indeterminate nodules fall into a “gray zone,” because their thyroid cells may not clearly look benign or cancerous on fine needle biopsy.
“This is why we are left in this conundrum,” he explained. “The ultrasound gives us a hint of higher or lower probability [of cancer], but unfortunately, it is not definitive. Therefore, thyroid nodules need to be worked up by specialists who are very experienced in all of these subtleties.” Patient preferences and disease-specific characteristics should be taken into consideration when making the final recommendation in patients with indeterminate nodules, he added.
The purpose of the current study was to gather data to aid decision-making in patients with indeterminate nodules, and clarify the three settings in which the decision about the extent of surgery is being made: the preoperative setting, during surgery itself, and the postoperative setting.
“The ultimate goal was to collect data that would allow for a better discussion and shared decision-making to take place between the clinician and the patient in terms of what’s best for the individual patient,” said Dr. Siperstein.
The retrospective study included 700 adult patients with thyroid nodules treated at the Cleveland Clinic Endocrinology & Metabolism Institute between March 2015 and February 2018. Patients underwent either hemithyroidectomy (lobectomy with isthmusectomy) or total thyroidectomy; in cases where metastatic disease was confirmed, therapeutic central neck dissection was performed. ATA guidelines were applied in the preoperative classification of patients.
“In counseling a patient for surgery, the risk of needing a more radical initial procedure or second surgery needs to be accurately explained. There are three points of care that can influence operative strategy[:] preoperatively by way of high-risk clinical factors, intraoperatively via anatomical findings, and postoperatively in response to unrecognized pathological features. Additionally, the patient’s personal value judgment and level of risk aversion should be taken into consideration.”— Moore et al
Tweet this quote
Independent indications for total thyroidectomy were found for 68.8% (205 of 298) of patients with indeterminate nodules, while the remainder (32.3%) were considered candidates for lobectomy. The risk of ultimately needing a total thyroidectomy was 19.4% (18 of 93) in lobectomy-eligible patients—in 4.3% (4 of 93) of patients, the risk was due to intraoperative findings, and in 15.7% (14 of 89) of patients, this risk was due to final pathology. Twenty-one percent of patients undergoing lobectomy were upgraded to a total thyroidectomy intraoperatively and 26.5% were upgraded postoperatively.
This is the first study to quantify the risk of patients needing total thyroidectomy in all three clinical settings, noted Dr. Siperstein.
“For about one-fifth of the patients who have passed the filter in the office—of being able to just have one lobe out—that decision was altered in the operating room,” he said. The proportion of patients with indeterminate nodules needing a second operation (total thyroidectomy) was 15.7%, as opposed to 26.5% of those with high-risk nodules.
“Again, this peppers my discussion with the patients,” added Dr. Siperstein. “Some patients will say to just take it all out the first time, while others will say, I’ll take the 25% chance that I’ll need to go back.”
Another surprising finding of the study was the high number of cancers arising from nodules on the other lobe (ie, the lobe without the primary lesion of interest), pointing to a need for a thorough assessment of both lobes.
“We found that if you have a nodule on the other side, and it is bigger than [1 cm], it has a 50% chance of being a second cancer,” said Dr. Siperstein. “That’s one of the eye-opening numbers that came out of this study that quickly alters the discussion with the patient.”
The study authors concluded, “In counseling a patient for surgery, the risk of needing a more radical initial procedure or second surgery needs to be accurately explained. There are three points of care that can influence operative strategy[:] preoperatively by way of high-risk clinical factors, intraoperatively via anatomical findings, and postoperatively in response to unrecognized pathological features. Additionally, the patient’s personal value judgment and level of risk aversion should be taken into consideration.”
Disclosure: For full disclosures of the study authors, visit link.springer.com.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.